Kristopher Dennis, MD, FRCPC

Moving forward, perhaps no recent development in the use of RT in metastatic prostate cancer has captured greater attention than the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC).

Patients with advanced progressive cancer require care plans that address their physical, emotional, and psychosocial needs, as well as their goals of care.